Stay updated on Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page revision label was updated to v3.5.3, replacing the previous v3.5.2, indicating a backend build update with no changes to study information.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check38 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the page.SummaryDifference0.1%

- Check52 days agoChange Detected- The site revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded results metrics (pathologic complete response rate, overall survival, disease-free survival) and counts of drug-related toxicities with posting dates; included investigator/site details (Arsen Osipov, MD; Cedars-Sinai; The University of Texas Health Science Center at San Antonio) and attached the Study Protocol and Statistical Analysis Plan document.SummaryDifference3%

- Check87 days agoChange DetectedA government funding lapse notice about data currency and NIH operations was added, and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.